Related Experiment Video

Updated: May 28, 2026

A 3D Organotypic Melanoma Spheroid Skin Model
08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

Melanoma and epigenetic treatment: past and future

Caterina Am La Porta1

  • 1Laboratory of Molecular Oncology, Department of Biomolecular Science and Biotechnology, University of Milan. caterina.laporta@unimi.it

Anti-Cancer Agents in Medicinal Chemistry
|November 3, 2011
PubMed

Insights

This review explores histone deacetylase inhibitors (HDACis) and microRNAs as novel epigenetic strategies for treating advanced melanoma. Further research is crucial to understand treatment toxicity and improve patient survival rates.

Area of Science:

  • Oncology
  • Dermatology
  • Epigenetics

Background:

  • Melanoma, the most aggressive skin cancer, often presents resistance to conventional therapies, especially in advanced stages.
  • Current treatments for metastatic melanoma yield limited survival benefits.
  • Epigenetic modifications present potential therapeutic targets for melanoma treatment.

Purpose of the Study:

  • To review the role of histone deacetylase inhibitors (HDACis) and microRNAs in melanoma treatment.
  • To critically discuss recent findings on epigenetic strategies for melanoma.
  • To highlight the need for further research into treatment toxicity and patient survival.

Main Methods:

  • Literature review of recent findings on HDACis and microRNAs in melanoma.
  • Critical discussion of current therapeutic strategies and epigenetic approaches.
  • Analysis of potential benefits and challenges of novel treatments.

Main Results:

  • HDACis and microRNAs represent promising epigenetic strategies for melanoma.
  • Combination therapies involving epigenetic agents may offer new perspectives.
  • Significant challenges remain in understanding and managing treatment-related toxicity.

Conclusions:

  • Epigenetic therapies, including HDACis and microRNAs, hold potential for advanced melanoma.
  • Further investigation into the toxicity profiles of these agents is essential.
  • Improved understanding is necessary to enhance survival outcomes for melanoma patients.

More Related Videos

Methylated DNA Immunoprecipitation21:24

Methylated DNA Immunoprecipitation

Published on: January 2, 2009

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Skin Cancer01:30

Skin Cancer

Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.